Teclistamab With Talquetamab Shows a Manageable Safety Profile in RRMM

Yael Cohen, MD, senior physician, Department of Hematology, Tel-Aviv Sourasky Medical Center, discusses the main safety findings from the phase 1/2 RedirecTT-1 trial (NCT04586426), which is evaluating the combination of teclistamab-cqyv (Tecvayli) and talquetamab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM).

According to Cohen, the safety data was manageable among patients with RRMM, including those with extramedullary soft tissue plasmacytomas.

Transcription:

0:08 | There were 93 patients that were included [in the trial] overall and of them, 34 were treated with the RP2R [recommended phase 2 regimen]. The median age was 65, and they had 4 prior lines of therapy as a median. About a third of the patients had soft tissue plasmacytoma, and this is a condition which is typically quite harder to treat. Over 20% had prior BCMA exposure, 75% were triple class refractory, and 90% were refractory to their last line of treatment. All in all, this is quite a tough patient population.

0:47 | As far as safety, there were really no surprises and the safety was manageable and was comparable to that of monotherapies. For hematologic toxicities, we had 12% febrile neutropenia, and as far as non hematologic malignancies, there were fewer discontinuations and we had a high rate of infections as can be expected, and [that] is typical for bispecifics, but less than 40% of the patients at RP2R had a grade 3 to 4 infection. There were 6 deaths on the study due to infections. The CRS rate was also comparable to what we are accustomed to. Most were grade 1 to 2 CRS, and 26% of the patients required tocilizumab [Actemra]. There were 5 cases of ICANS, however, only 1 was a transient grade 3, and all the rest were grade 1 events. All in all, safety was manageable with a low rate of discontinuation.